Simvastatin Tablet, Film Coated
Product Images NDC 51655-113

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Simvastatin (NDC 51655-113). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 113 26 Rev A 02 23)

NDC 51655-113-26 Rev. A 0223 Simvastatin Tablets, USP 40 mg, 90 Tablets. This medication is prescription only and should be stored in its original container. Dosage information can be found in the package insert. Children should not have access to this medication. The medication is manufactured by Biocon Pharma Inc. and repackaged by Northwind Pharmaceuticals. The tablets contain 40mg of Simvastatin USP. The lot number is 0000000000, and the medication has an expiration date of 00/00/0000.*

FDA Label Image

Footnote For Table 3 (Footnote For Table 3)

This text provides information on the potential inhibitors of CYP3Ad, including ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone. It also mentions simvastatin acid, the effect of grapefruit juice on simvastatin pharmacokinetics, and the dosing regimen for grapefruit juice and simvastatin. This information may be useful for healthcare professionals treating patients with simvastatin or other medications metabolized by CYP3Ad.*

FDA Label Image

Figure 9 (Simvastatin 10)

FDA Label Image

Table2 (Simvastatin 2)

The table shows the adverse reactions reported by patients treated with Simvastatin when compared to Placebo. The adverse reactions are categorized into different body systems like cardiovascular, digestive, musculoskeletal, etc. Some of the reactions that were reported in a higher percentage of patients treated with Simvastatin when compared to Placebo were abdominal pain, atrial fibrillation, constipation, diabetes mellitus, myalgia, insomnia, and eczema.*

FDA Label Image

Structure (Simvastatin 3)

FDA Label Image

Table 3 (Simvastatin 4)

FDA Label Image

Table 4 (Simvastatin 5)

FDA Label Image

Figure 5 (Simvastatin 6)

This appears to be a medical study report presenting the characteristics and risk ratios of patients with or without certain cardiovascular conditions who were administered different treatments. The text contains tables with numbered characteristics and their corresponding values. The study is likely investigating the efficacy of Simvastatin and/or Placebo in preventing major vascular and/or coronary events.*

FDA Label Image

Figure 6 (Simvastatin 7)

FDA Label Image

Figure 7 (Simvastatin 8)

FDA Label Image

Figure 8 (Simvastatin 9)

FDA Label Image

Table 1 (Table1)

This text provides a table of drug interactions that are associated with an increased risk of myopathy and rhabdomyolysis. The interacting agents listed in the table include strong CYP3A4 inhibitors, HIV protease inhibitors, verapamil, diltiazem, amiodarone, and others. Prescribing recommendations are provided based on the interactions listed. The text also warns against exceeding certain dosages of simvastatin in patients taking certain medications and advises against consuming grapefruit juice.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.